Research Analysts Offer Predictions for EW FY2025 Earnings

Edwards Lifesciences Corporation (NYSE:EW) – Research analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for Edwards Lifesciences in a report issued on Friday, October 31st. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will post earnings per share of $2.60 for the year, up from their previous forecast of $2.51. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q4 2025 earnings at $0.62 EPS, FY2027 earnings at $3.31 EPS, FY2028 earnings at $3.76 EPS and FY2029 earnings at $4.21 EPS.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm’s revenue was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS.

A number of other research analysts also recently weighed in on EW. The Goldman Sachs Group set a $104.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Friday. BTIG Research upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Tuesday, July 29th. Citigroup boosted their price objective on shares of Edwards Lifesciences from $95.00 to $96.00 and gave the stock a “buy” rating in a report on Friday, October 31st. JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Finally, Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a research note on Monday. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Stock Up 1.3%

EW opened at $84.13 on Monday. The business has a 50-day moving average of $77.68 and a 200-day moving average of $77.14. Edwards Lifesciences has a fifty-two week low of $64.89 and a fifty-two week high of $87.09. The company has a market capitalization of $49.39 billion, a PE ratio of 12.11, a price-to-earnings-growth ratio of 3.97 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rosenberg Matthew Hamilton bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $28,000. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $26,000. True Wealth Design LLC raised its holdings in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the period. NewSquare Capital LLC raised its holdings in shares of Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 134 shares during the period. Finally, SouthState Corp bought a new position in Edwards Lifesciences in the 1st quarter valued at about $27,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.